finance.yahoo.comOCT 202 min read$MNKD

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.

Original reporting

finance.yahoo.com

Published Oct 20, 2026, 8:03 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 20, 2026, 8:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$MNKDBullishMed

Why it matters

The announcements provide fresh growth catalysts for MNKD, potentially shifting analyst expectations and prompting short‑term buying interest.

Market read

First‑report of pipeline progress and product launch may drive MNKD stock movement.

What to watch

Cash runway is limited; execution risk for scaling FUROSCIX remains.

Relevance 8/10Novelty 8/10Timing: now

Background

MannKind focuses on inhaled products; recent updates include a new IPF program and the launch of an auto‑injector version of its furosemide drug.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MNKDBullishHigh confidence

Context

MannKind announced the GenRALD inhaled IPF program may enter human testing this year and launched the FUROSCIX ReadyFlow auto‑injector with strong early adoption.

Expected impact

likely upside as market prices in expected Phase 2 data and FUROSCIX adoption

Evidence & confidence

First‑report of new inhaled IPF program timeline and strong early sales of FUROSCIX suggest revenue expansion and potential profitability.

Market effects

Sector

May boost sentiment for inhaled therapeutics and niche biotech peers.

Regional

Limited to US biotech sector.

Global

Low; primarily affects MNKD and similar small‑cap biotech stocks.

Counterpoint

What could challenge this read

If Phase 2 data disappoint, the hype could reverse quickly.

Key entities

company
MannKind Corporation
US‑listed biotech developing inhaled therapies.

Read at source ← All news

OCT 10

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.

stocktitan.net2 min

OCT 10

$MNKDMedAI 8/10

MannKind Corporation (MNKD) Posts Data Backing Furoscix ReadyFlow IV-Equivalent Diuresis

MannKind (MNKD) presented data at HFSA 2026 showing Furoscix ReadyFlow's subcutaneous injection achieved IV-equivalent exposure and diuretic effect. The study demonstrated flexibility in injection sites, including the thigh and arm. This follows recent FDA approval and supports the company's clinical equivalence claims.

tradingview.com1 min

SEP 9

$MNKDMed

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

MannKind (MNKD) partners with Rose Pharma to develop an inhaled weight-loss drug, ROSE-010, using its Technosphere technology. MannKind will receive an equity stake and potential royalties. ROSE-010 has shown promise in reducing calorie intake and weight loss in previous studies. MNKD shares rose 1.7% in pre-market trading.

finance.yahoo.com6 min

SEP 9

$MNKDMed

A rapid-acting, short-duration inhaled treatment is being developed for weight management

MannKind (MNKD) and Rose Pharma have partnered to develop ROSE-010, an inhaled GLP-1 drug for weight management. MannKind licenses its Technosphere tech, gaining equity, royalties, and a board seat. Rose Pharma leads development and commercialization. The drug may also target irritable bowel syndrome.

stocktitan.net2 min

SEP 5

$MNKDHighAI 8/10

MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children

MannKind (MNKD) shares rose 5% after FDA approved Afrezza for diabetes treatment in children aged 6+. The approval follows Phase 3 trial data showing Afrezza's noninferiority to injections in HbA1c changes, with higher patient satisfaction and less weight gain. Afrezza uses Technosphere tech for rapid insulin delivery via inhalation.

stocktwits.com2 min

AUG 24

$UTHRMedAI 9/10

FDA accepts United Therapeutics' ralinepag NDA for PAH

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

allsci.com2 min